<DOC>
	<DOC>NCT00298038</DOC>
	<brief_summary>The purpose of this study is to determine if the study drug is safe and effective in preventing Hepatic Encephalopathy (HE).</brief_summary>
	<brief_title>A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Must sign an Informed Consent Form In remission from past hepatic encephalopathy (HE). Appropriate birth control measures More than or equal to 18 years of age. Must be potential for benefit from treatment. Recent prior HE episodes Capable and willing to comply with all study procedures. Subject has personal support available Has a certain Model End Stage Liver Disease (MELD) score Recent TIPS placement or revision Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include. Allergies to the study drug or similar drugs. Laboratory abnormalities. Recent participation in another clinical trial History of noncompliance Pregnant or at risk of pregnancy, or is lactating. Recent alcohol consumption Active bacterial or viral Infections Bowel issues Active malignancy. On a prohibited medication. Liver transplant expected in near term Lactulose intolerance Subject shows presence of intestinal obstruction or has inflammatory bowel disease. Ongoing or recent GI bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>